Dr. Timothy E. Bates is the founder and Chief Scientific Officer of Drugs With A Difference Limited. Dr. Bates has over 33 years’ experience in biomedical research. The company’s anti-cancer drug technologies are continually being invented by Dr. Bates, taking advantage of his extensive knowledge of cancer cell biology, pharmacology and biochemistry and the unique biochemical assays (precise methods to measure specific biochemical parameters) he has developed, which are not available anywhere else in the world. Amongst other esteem indicators, Dr. Bates was selected as one of only 32 members in the U.K. of the external assessor panel for the NHS Evidence section of the National Institute of Health and Care Excellence (NICE), where his experience in biomedical research and development is used in the specific areas of (1) Drugs and Medical Devices and (2) Research.
Dr. David Cavalla is the U.K.’s leading expert in drug repurposing and the CEO of Numedicus limited. David is responsible for our drug repurposing strategy and implementation and the author of "Off-label prescribing. Justifying unapproved medicine" published by Wiley, 2015.
Mr. David Scott is in charge of sales of IP and the negotiations surrounding the construction of "heads of terms" and other aspects of drug licensing. David is an internationally respected expert in deal brokering, marketing, strategic planning, finance, business development and acquisitions, and the author of the best-selling report, "Scrip's Practical Guide to Pharmaceutical Licensing".
Dr. Steve Jones is in charge of all matters relating to patenting our drugs and associated intellectual property development. In 2000 Steve founded Adamson-Jones (Patent, Design & Trade Mark Attorneys), based at BioCity Nottingham, where he is the Senior Partner. Steve has over 30 years’ experience in pharmaceutical patenting, with particular emphasis on the field of drug formulations.